@article{TCR9524,
author = {Paolo Nuciforo},
title = {Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 3},
year = {2016},
keywords = {},
abstract = {Trastuzumab in breast cancer exemplifies the paradigm of successful targeted therapy. This anti-HER2 monoclonal antibody reduces the risk of recurrence by half when combined with standard chemotherapy (1-3). Its target—HER2—is overexpressed in 20% of breast cancers and testing for HER2 positivity is the sine qua non for anti-HER2 therapies. Consensus guidelines have been developed for the definition of HER2-positive (HER2+) tumors. HER2 protein expression has to be 3+ by immunohistochemistry (IHC) or the gene has to be amplified by fluorescence (FISH) or chromogenic (CISH) in situ hybridization (4).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/9524}
}